Randomized phase II trial of fulvestrant alone or in combination with bortezomib in hormone receptor-positive metastatic breast cancer resistant to aromatase inhibitors: a New York Cancer Consortium trial

MLA

Tessa Cigler, et al. “Randomized Phase II Trial of Fulvestrant Alone or in Combination with Bortezomib in Hormone Receptor-Positive Metastatic Breast Cancer Resistant to Aromatase Inhibitors: A New York Cancer Consortium Trial.” Npj Breast Cancer, vol. 2, Dec. 2016. EBSCOhost, https://doi.org/10.1038/npjbcancer.2016.37.

APA

Tessa Cigler, Charles L. Shapiro, Miguel A. Villalona-Calero, P Klein, George Raptis, G. Thomas Budd, Anupama Goel, Ellis G. Levine, Joseph Baar, Yelena Novik, Michael Naughton, Joseph A. Sparano, Kevin Kalinsky, Dawn L. Hershman, Paul J. Christos, Gang Han, Eleni Andreopoulou, John J. Wright, Kerin B. Adelson, … Doris Germain. (2016). Randomized phase II trial of fulvestrant alone or in combination with bortezomib in hormone receptor-positive metastatic breast cancer resistant to aromatase inhibitors: a New York Cancer Consortium trial. Npj Breast Cancer, 2. https://doi.org/10.1038/npjbcancer.2016.37

Chicago

Tessa Cigler, Charles L. Shapiro, Miguel A. Villalona-Calero, P Klein, George Raptis, G. Thomas Budd, Anupama Goel, et al. 2016. “Randomized Phase II Trial of Fulvestrant Alone or in Combination with Bortezomib in Hormone Receptor-Positive Metastatic Breast Cancer Resistant to Aromatase Inhibitors: A New York Cancer Consortium Trial.” Npj Breast Cancer 2 (December). doi:10.1038/npjbcancer.2016.37.